139 results on '"Patt, Marianne"'
Search Results
2. Ions and small molecules as radiopharmaceuticals
3. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
4. First Safety and Efficacy Data with the Radiohybrid177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
5. Noradrenergic control of neurobehavior in human binge‐eating disorder and obesity (NOBEAD): A smartphone‐supported behavioral emotion regulation intervention study protocol integrating molecular brain imaging
6. The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe
7. Cerebral Blood Flow Measurement with Oxygen-15 Water Positron Emission Tomography
8. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
9. Die „sachkundige Person“ in der Radiopharmazie – Herstellungserlaubnis oder nicht?
10. Increase in serotonin transporter binding in patients with premenstrual dysphoric disorder across the menstrual cycle: a case-control longitudinal neuroreceptor ligand PET imaging study
11. Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal
12. Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings
13. Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies
14. Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies
15. Availability of Central α4β2* Nicotinic Acetylcholine Receptors in Human Obesity
16. Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity
17. HPA Axis Responsiveness Associates with Central Serotonin Transporter Availability in Human Obesity and Non-Obesity Controls
18. Neuronal injury assessment with early-phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol β-amyloid-PET recordings
19. Differential Diagnosis Between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid-β Imaging?
20. Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
21. Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [18F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies
22. PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders
23. Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center
24. 18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
25. Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends
26. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre
27. EANM guideline on quality risk management for radiopharmaceuticals
28. Tau deposition patterns are associated with functional connectivity in primary tauopathies
29. Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies
30. EANM position on the in-house preparation of radiopharmaceuticals
31. Aktuelle radiopharmazeutische Entwicklungen für die theranostische Anwendung
32. Feasibility of short imaging protocols for [ 18 F]PI‐2620 tau‐PET in progressive supranuclear palsy
33. Cerebral Blood Flow Measurement with Oxygen-15 Water Positron Emission Tomography
34. Central Noradrenergic Neurotransmission and Weight Loss 6 Months After Gastric Bypass Surgery in Patients with Severe Obesity
35. Kamingespräch „§ 13 (2b) AMG in der nuklearmedizinischen Therapie” – eine Follow-up-Veranstaltung der NuklearMedizin 2020 – Digital
36. Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620
37. Aktuelle radiopharmazeutische Entwicklungen für die theranostische Anwendung
38. Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?
39. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
40. Zum Rechtsstatus von Kits in der Herstellung von Radiopharmaka
41. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
42. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
43. Feasibility of Short Imaging Protocols for [18F]PI-2620 Tau-PET in Progressive Supranuclear Palsy
44. Regulatorische Anforderungen an Radiopharmaka in Deutschland: die Fachgesellschaft im behördlichen Dialog
45. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)
46. Higher HbA1c levels associate with lower hippocampal serotonin transporter availability in non-diabetic adults with obesity
47. 18 F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort)
48. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
49. Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension
50. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls – A hybrid PET/MRI study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.